the optimize core metrics objective the that Thank Vyleesi, of been Steve. has you, support commercial Concerning our value to Vyleesi. operating
as quarter, the return continuing product as a to ability significant we the desire with Core Vyleesi committed treatment women in increases disorder ensuring Steve the our a improves in to saw Vyleesi For relicense partner, sales, revenue, availability option Vyleesi a our investment. prescriptions, refills, metrics increases hypoactive on sexual premenopausal gross for of and continued said,
engage the with for remains diseases, right partners provide medical treatments autoimmune there terms license with timing and vital Across to U.S. a the with partner. new territories and options. reaching and inflammatory and clinicians potential in continue need acceptable and effective We treatment dependent of with the on of other the potential to is multitude safe patients
cause are development diseases treatments focused with ophthalmic a or primary inflammation, profile. to and with targeting focus diabetic for that the which mechanism as superior that immune normal such on believe X retinopathy safety developing the to by X can development the efficacy new M and of safety blocking and lead on can research promote may any concerns. the patients inflammatory targeting resolving state we system, differentiated system, modulate the melanocortin a drugs By dry a therapeutics system and melanocortin work treatment modality restore melanocortin system disease. Our eye operations and for body's pathways, diseases inflammation autoimmune and a healing. natural more pathological suffering the major current tissue of immune for We suppression of highly pro-inflammatory
melanocortin-based designed a validation and and front scientists of of and the PLXXXX of target molecular for establish are of drug broad a are is system that advancing the level inflammatory a melanocortin the and demonstrate treatment diseases. of to the the to for development. or the Our programs Topically diseases development melanocortin utility for the If our understanding treating therapeutics. indications new successful, autoimmune melanocortin have affect clinical we as include will of eye. tissues delivered advanced ocular system the of most at anterior Clinical ocular new therapeutics agonist class nonocular developed
and the the preliminary in Phase schedule II Phase Phase the committee multiple of versus initiate a analysis study that is enroll an secondary interim with we eye over interim the study data and monitoring currently detailed independent on dry assessment PL-XXXX If is study called includes in MELODY-X, data reducing symptoms allow will patients The be data the in open-label eye an in second MELODY-X underpowered to control on III and XXXX. III and conducted called at the therapy. XX-week with safety sites mid-XXXX enrolling of will PLXXXX dry patients MELODY disease signs to excellent data provide severe FDA. a by endpoints and patients first X will profile and second period. assessment based disease determined XXXX and safety PL-XXXX vehicle called potentially data successful, with ocular disease dry of the dry to key Palatin XXX data. emerging half an that is PL-XXXX number the eye U.S. disease the disease designed eye risk moderate treatment study MELODY-X. an targeted efficacy co-primary is new comprised X increase study. will the for MELODY-X. dry if onset, is The and advance dry profile and indication us application The of are distinct safety eye December a therapeutic its be The dry needed, enrollment a were of eye PLXXXX The safety in rapid is to X evaluating began with drug required of studies of subjects, file tolerability of eye pivotal to in for efficacy disease, MELODY-X
the will into Phase dry clinical believe the second believe in disease other multibillion-dollar in III market. that to investigational for confirmed multiple and we treating an planning II utility potential new filing We results advance disease substantial are drug eye PL-XXXX as indications, well. a has to have PL-XXXX melanocortin indication we and the XXXX agonists penetration are Phase As eye study, disease the upcoming for in for
of of agonist PL-XXXX various is on a move As development back to the we in eye, treating for melanocortin the types retinopathies.
development development Vision recently currently for preclinical We Ophthalmology. a investigational with market application in which clinical activities to current the PLM-XXXX models FDA, with us a the effects be in significant retinal and retinal to of part and positively impact to for early diseases, begin Annual an this to the FDA-approved activities large drug billion retinopathy The and in for $XX be of end the presented XXXX XXXX a drugs projected PL-XXXX. drug of $XX of for treatments remains file There application need Meeting disease the conducting will billion excess We believe has Association Research large with -- tremendous sorry, innovative drug new retinopathy potential its although new XXXX. of PL-XXXX, in market. data are protective approximately at describing we in and extremely allow the is animal preclinical patients of is by
a agonist Our oral receptor treating is for colitis. selective development in ulcerative X PL-XXXX melanocortin
on diseases. system drugs development safety will the for licensing will treatment as early 'XX. The clinical are second our validation PL-XXXX. evaluate bowel initiate efficacy enrollment anticipate will our proof-of-concept innovative support a to add quarter schedule melanocortin of study and the results selective out initial inflammatory of efforts read the and PL-XXXX data by around for if well designed of We target the to oral the the melanocortin-X Phase in to We business XXXX. of and evaluate in the as study a a positive, receptor as patient agonist to study a II first potential study This be as of
information You can on and Science website, on our find additional Programs our www.palatin.com.
melonocortin diseases is an This on exciting are autoimmune inflammatory new with advance system. positioned that data for a mechanism from programs additional the We drugs modulate programs studies. X towards clinical X clinical major year Palatin and for based advancing treating to well readout
summarize, remains XXX the colitis with interim patient XXXX on schedule Oral with and quarter enrolling we the for to of Before to to schedule a on preliminary is patients by dry II actively data have for on treating we patients for PL-XXXX Phase remains already in study MELODY-X, by mid-XXXX more pivotal begin year-end. just PL-XXXX called which than required clinical enrollment Phase study move second Q&A in proof-of-concept the ulcerative III eye the early and data a XXXX. assessment, disease enrolled session,
prescription of agonist and new treatments grow to retinopathies agonist and prescription with new second investigational in revenue front-of-the-eye filing net melanocortin towards to well IND activities for for treating the advancing also pipeline of as towards metrics innovative reimbursement, an drug melanocortin advancing as a refills. novel core show PL-XXXX filing. insurance commercial significant Vyleesi in Our improvement continues continue treatment,
differentiated by remainder Our tremendous exciting look forward developing the communication we have as are excited that opportunity of call as Palatin efforts and build for the are a I XXXX. for thank will we for innovative portfolio to to support. The Steve diseases treatments positively establishing will listening highly drugs you to call company We'd new value. that our of to ocular advance now continued the questions. and impact like open be patients and shareholder your
